To evaluate the reliability and validity of serum carcinoembryonic antigen (CEA), tissue polypeptide-specific antigen (TPS), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in monitoring palliative chemotherapy in advanced colorectal cancer (ACRC).
Introduction
In advanced colorectal carcinoma (ACRC), chemotherapy is often used for palliation. The main purposes of the treatment are to decrease tumour-related symptoms or, alternatively, to prolong a symptom-free period and to prolong survival without excessive toxicity. Using the regimens available today, only about half of ACRC patients have a meaningful positive outcome of treatment [1] . A substantial proportion of patients thus does not receive any meaningful gain from the treatment, and just experience the side effects. The cost to society and the demands on the health service are not negligible. Thus, better predictors for treatment outcome are warranted. These predictors should ideally be available prior to therapy, but factors that work early after treatment initiation may also be of value since they can decrease toxicity and costs. A number of clinical variables, among which performance status is the most widely recognised, may predict therapy response [2] [3] [4] but knowledge of which patients are likely to respond is limited.
The tumour marker carcinoembryonic antigen (CEA) [5] has frequently been used for the last 30 years in a variety of clinical situations, including monitoring of chemotherapy treatment in ACRC, although a proper validation of the use of this marker for monitoring has never been performed [6] [7] [8] .
Tissue polypeptide-specific antigen (TPS) has been reported to be a useful tumour marker in various malignant diseases [9] [10] [11] [12] [13] [14] and as a predictor for response in monitoring chemotherapy in various advanced gastrointestinal carcinomas [11, 15] . TPS measures a specific epitope structure of soluble fragments of human cytokeratin 18 in the circulation [16] .
Angiogenesis is a rapidly expanding research field, increasing the understanding of tumour growth and the metastatic process. Measurements of angiogenic peptides such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in serum have been presented in several pilot studies, and indicate clinical impact as markers for staging, prognosis [17] [18] [19] [20] [21] [22] [23] [24] and for prediction of outcome in the palliative setting in gastrointestinal cancer [24] .
In 1992, we began to prospectively collect serum prior to all chemotherapy courses in patients with ACRC. The following research questions were raised. (i) Can tumour markers prior to therapy predict outcome of palliative chemotherapy? (ii) Can tumour markers predict response early during therapy before any imaging technique may reveal a change in tumour size? (iii) Is it necessary to use imaging for response evaluation, if tumour markers turn out to have the same capability to predict prolonged survival and palliation of symptoms? Even if radiological assessment is the gold standard for response evaluation, it is still a surrogate marker for the main objectives of palliative chemotherapy, namely to prolong survival and to relieve/delay the occurrence of tumour-related symptoms. Here we report the results of measuring CEA, TPS, VEGF and bFGF according to tumour response and subjective outcome.
Materials and methods

Design
Between November 1992 and January 1998, 87 consecutive patients with ACRC were treated with 5-fluorouracil (5-FU) and leucovorin according to the Nordic schedule [25] at the Department of Oncology, Akademiska sjukhuset, Uppsala. Patient characteristics are shown in Table 1 . Most patients were included in a randomised trial. Thirty-two patients participated in a study where patients were randomised between 5-FU given as a bolus injection over 3 min or as a short-term infusion over 15 min [26] , and 33 participated in a study (not yet published) where they were randomised to one of three different doses of 5-FU (400, 500 or 600 mg/m 2 ).
The remaining 22 patients were treated with the same regimen outside the studies for various reasons, mainly due to being >75 years old. They were then treated with 5-FU 500 mg/m 2 as a bolus injection followed by leucovorin infusion after 30-40 min given as 60 mg/m 2 on 2 days. The courses were repeated every 14 days. Treatment continued until disease progression or until development of severe toxicity. If disease stabilisation was seen after 8-12 courses, it could also be interrupted if this was considered to be a better palliation. Mean duration of the treatment was 5 months (range 1-33 months). The median survival time was 8 months (range 1-≥35 months) and four patients are still alive.
The study was approved by the local ethics committee.
Assessment of tumour response
Objective and subjective response evaluations were performed according to study protocols [25, 26] every second month, i.e. after every fourth leucovorin treatment. Objective tumour response was assessed according to standard criteria. A complete response (CR) or partial response (PR) and stable disease (SD4) had to be present at two consecutive evaluations, i.e. with a minimum duration of 4 months. Patients who had a response or stable disease after 2 months and then progressed before the next evaluation were designated as stable disease for 2 months (SD2). In all other instances, progressive disease (PD) was recorded. All responses among patients in the trials have been reviewed independently. All assessments were carried out with computed tomography (CT) scan and/or other radiological examinations. In the following text, when the term objective response is used, it includes CR, PR and SD4. In previous studies from the Nordic group, patients with CR, PR or SD4 have, as a group, shown clinical benefit from the treatment, with prolonged survival and symptom improvement [27] .
A subjective response evaluation was performed by the treating doctor at the same time as the objective response evaluation. The subjective evaluation was based on a personal interview. A subjective response (designated improved) was present when the patients symptomatology had improved for at least 4 months with no signs of severe adverse treatment effects. If the patients did not have any symptoms of the disease prior to treatment and at the evaluation, they were designated symptomfree. Symptom-free and improved patients are grouped together under the category 'improved'. Both the objective and the subjective response evaluations and their durations were identical to those used in previous trials [25, [28] [29] [30] .
Serum sampling
Serum was obtained from all patients before chemotherapy. Subsequent sampling was performed prior to all treatment courses, i.e. with an interval of 2 weeks. The serum samples were aliquoted and immediately frozen at -20°C and stored until assayed.
Tumour marker assessment
All tumour markers (see below) were retrospectively analysed at baseline, after 2 and 4 weeks of treatment and at the same time as the first radiographic examination prior to the fifth course (after 10 weeks). Among patients with a normal baseline tumour marker, no calculation of change for this specific marker was performed. Altogether, 923 samples have been analysed. A further 126 samples have not been analysed due to missing samples or insufficient quantity of serum. Angiogenesis factors. A pilot study was performed in 33 patients in this cohort with both VEGF and bFGF. VEGF indicated some correlation with response to therapy, and therefore this marker was enrolled. bFGF did not reveal any correlation to response or to survival. Elevated bFGF values were also only seen in a minority of the patients; therefore, no further determination of bFGF was performed.
VEGF measurements. A quantitative sandwich ELISA technique was used (human VEGF; Quantikine, R&D Systems, Minneapolis, MN, USA). The VEGF concentration in the samples was determined by comparing the optical density of the samples to the standard curve. The lowest detectable value for VEGF was 9 pg/ml. The upper normal limit of VEGF is 500 pg/ml (95th percentile) [17] .
bFGF measurements. An ELISA technique was used to measure bFGF (human bFGF; Quantikine R&D). The lowest detectable value for bFGF was 0.25 pg/ml. The upper normal limit was determined to be 7.25 pg/ml [17] . The specificity of the assay has been verified by the manufacturer with many different recombinant human and mouse cytokines.
Statistical analyses
Comparisons of proportions between groups were performed by χ 2 analyses.
Survival curves were constructed according to the Kaplan-Meier product-limit method and log rank test was used to test differences. Correlations were studied with Spearman's rank correlation test. The proportional Cox's hazards model was used to evaluate the importance of prognostic variables one by one and in multivariate analyses. Comparison of changes in tumour marker levels in relation to objective and subjective responses were expressed in terms of sensitivity and specificity according to conventional definitions.
Results
CEA measurement
Eleven patients (13%) were CEA negative (CEA <3.1) at baseline and all remained negative throughout the follow-up period. These eleven patients had marginally significantly shorter survival times (P = 0.06) than those with elevated levels. Baseline CEA did not correlate with response or survival ( Table 2) , whereas a correlation was seen with TPS (P <0.001). The CEA values decreased by at least 25% during treatment in some patients, and significantly more often in patients with an objective and a subjective response than in those with no response ( Table 2 ). The decrease was not very rapid, and in most of the patients, it was not detectable until after 10 weeks of treatment. The relations between the changes in CEA values and objective and subjective response after 10 weeks are shown in Table 3A . The sensitivity for clinical response was, however, not particularly high, even after 10 weeks (Table 3B ). The specificity was much higher, i.e. a decrease was seen in few patients without a response.
TPS measurement
Eight patients (9%) had normal TPS values at baseline. These patients had a high Karnofsky performance status (KPS) (seven had KPS 100 and one KPS 90), seven of eight responded to therapy (five PR, two SD4, one SD2) and they had a significantly better survival time (median 17 months) than those with elevated levels (median 8 months) (P = 0.01). Overall, baseline TPS correlated with survival, but not response (Table 2 ). Median survival time was 12 months for values <500 U/l and 6 months for high TPS values (Figure 1 ). There were strong correlations between baseline TPS and both performance status and haemoglobin (P = 0.001). The changes in TPS levels during treatment, and sensitivity and specificity during treatment are presented in Table 4A and B.
A TPS decrease as early as after 2 and 4 weeks indicated response to treatment, with sensitivity >70%. A decrease was, however, seen in several patients who later did not show a response, and the specificity was thus low. After 10 weeks the differences in outcome became more clear. All but two patients who were objective responders had a lower TPS value (>25%) at 10 weeks compared with baseline value. The specificity still remained rather low (65-70%), since four patients continued to have a decrease in the absence of any response (Table 4B) .
VEGF measurement
Forty-eight patients (54%) had elevated VEGF values at baseline and changes in VEGF values were only calculated among these patients. Ninety-four per cent of all patients had decreasing values, but neither baseline VEGF nor the changes predicted response or survival ( Table 2) . Irrespective of the determined cut-off level, the sensitivity and specificity for all responses at all time points were between 55% and 65% (data not shown).
Baseline bFGF values
Only five (15%) of 33 patients had elevated bFGF values at baseline. bFGF values correlated significantly to VEGF but not to any of the other above-mentioned parameters (data not shown). Since only a minority of the patients had elevated bFGF values, further analyses were not performed.
Other markers for prediction of response and survival
There were no statistically significant differences in survival or response with respect to age, gender or primary tumour site (rectum or colon). Performance status correlated significantly to both response and survival, and baseline haemoglobin values to survival (Table 2) .
Tumour markers used together
The sensitivity and specificity for response and prolonged survival did not increase when TPS and CEA were used together compared with those values calculated by TPS alone, either in univariate analyses or in multivariate analyses. Because patients with one or two normal baseline tumour marker levels were excluded, fewer patients were used in this group. When either of the tumour markers was used together with subjective response, the sensitivity and specificity for an objective response was not increased compared with subjective response only. As shown in Table 2 , subjective and objective responses were highly correlated.
Discussion
This study attempted to clarify the practical role of measuring different tumour markers in patients with ACRC treated with palliative chemotherapy. Three research questions were raised. Can two old and two new potentially valuable tumour markers predict tumour response (i) prior to therapy or (ii) early during treatment, and (iii) can they replace radiological assessments. TPS measurements appear to be useful for these purposes and they are clearly superior to CEA measurements. TPS baseline values were not correlated with whether a response occurred or not, but were with better survival, and survival was particularly favourable among patients with normal TPS value. An early TPS evaluation (after 2 and 4 weeks, i.e. after the first and second treatment course) indicated clinical outcome, with sensitivities ∼75% but with lower specificity. At 10 weeks a TPS value decrease of >25% correlated significantly, in univariate and multivariate analyses, with both objective and subjective responses with sensitivity and specificity of ∼85% and 70%, respectively, and with survival. The results are in accordance with other studies that have explored any of the above research questions when monitoring patients with breast, lung and various gastrointestinal cancers [11, 15, 31, 32] .
Baseline CEA levels, in contrast, did not give any clinically meaningful prognostic or predictive information about response. After 2 and 4 weeks, very few patients showed a decrease of >25%. At 10 weeks, the sensitivity for response was only 45%, although the specificity was higher, at 88%. Thus, a decrease in responding patients was seen considerably more often using TPS than CEA, whereas a decrease in nonresponding patients was less frequent using CEA. Although the CEA changes after 10 weeks correlated significantly with response and survival in univariate analyses but not in multivariate analyses, the low sensitivity limits its use clinically. Repeated CEA measurements during therapy have been indicated in several reports as valuable in predicting response. The conclusions about the value of repeated CEA measurements, however, differ considerably between the reports, which often is the case when studies are mostly retrospective and based on small numbers of patients [33] [34] [35] [36] [37] [38] [39] [40] [41] . Hamm and Cripps [6] could not find any benefit of monitoring therapy with CEA in their own study or in an overview of the collected literature. Two other reviews came to somewhat contradictory conclusions [7, 8] . Similar to our study, Hanke et al. [41] could not show that a CEA or a CA 19-9 rise after 6 weeks of 5-FUleucovorin treatment were appropriate for recording disease progression. PD was rarely seen among 43 patients if CEA levels were falling (specificity 99% and 88% in this study). Several authors have suggested usefulness in indicating PD after a period of treatment [8, 37, 39, 41] . The American Society of Clinical Oncology (ASCO) guidelines [42] from 1996 stated that existing data were not sufficient to recommend routine use of CEA alone for monitoring response to chemotherapy. However, if no alternative test was available to detect a response, it was suggested that CEA should be assayed at the commencement of treatment for metastatic disease and every 2-3 months during active therapy. This study of homogeneously treated patients according to prospective protocols could not detect any clinically meaningful information from monitoring with serial CEA measurements. Combining CEA and other tumour markers or clinical parameters did not add further information. Thus, the ASCO guidelines are still valid and efforts should be made to objectively verify tumour extent prior to therapy, and not to rely solely upon an elevated CEA level. TPS, rather than CEA, may better separate responding from non-responding patients if therapy is initiated without measurable or otherwise evaluable disease.
Only about half of our patients had elevated VEGF values and 15% had elevated bFGF values. There was no correlation between the levels of these angiogenetic peptides and survival or response, either at baseline or at an early evaluation. Therefore, this study has not been able to confirm the results from small pilot studies claiming potentially valuable information from VEGF and bFGF in the palliative setting among patients with ACRC [18-21, 23, 24] .
Of interest is the striking finding that several patients, regardless of outcome, have a rapid and clear decrease in TPS and an even more definite decrease in VEGF after initiation of chemotherapy. The explanation of this is not clear, but needs to be explored further. We have previously speculated that the decrease in TPS levels indicates some tumour cell death in most patients (∼75%) with gastrointestinal cancer, but this cell death is not sufficient to give either a subjective response seen in 40% to 50% of the patients or an objective response in 10% to 25%, depending upon primary tumour site [15] . In order to qualify as a response, it must also have a minimum duration, here 4 months. Concerning VEGF, Verheul and Pinedo [43] found that the level correlated highly with platelet count. They did not find any direct relationship with tumour burden. Most cytotoxic agents, and 5-FU, influence platelet counts. The mechanisms behind the decrease of TPS and VEGF serum levels may thus be different.
This study was prospectively designed to be able to address the question of the practical value of measuring tumour If toxicity to the first one or two courses is considered high by the patient, a clear decrease in TPS values after 2 or 4 weeks may indicate that a response is reasonably likely, and the patient may more easily accept the toxicity. Conversely, if no decrease is seen, the probability of a response is very low, and treatment could be terminated. If, on the other hand, toxicity is low, the sensitivity and specificity are not high enough to allow any recommendation of therapy change at this early time point. After 2 months of treatment, a lack of a decrease or an increase of TPS levels is a strong indicator of no response, and a confirming imaging investigation could be avoided. Similarly, with a clear decrease in values together with unequivocal symptomatic benefit and acceptable toxicity, the costs of imaging could be saved, and therapy continued. The cost of TPS measurement is low (Swedish crowns, SEK 125) compared with, for example, a CT scan of the liver (SEK 2500). Finally, it must be stressed that a complete concordance between imaging and changes in serum markers levels can never be reached. When the above discussions were retrospectively applied to the patient histories, we noticed several patients where knowledge of the TPS values would have influenced the practical care of the patients or being cost saving. The same rarely happened using CEA.
Conclusions
The results in this study indicate that repeated measurements of TPS levels during therapy can be of clinical relevance, primarily as a marker of lack of response. In this context, it is clearly superior to the commonly used CEA. We strongly question the wide use of CEA, both in clinical trials and for routine use, when monitoring 5-FU-based chemotherapy in patients with ACRC. VEGF and bFGF did not provide any relevant clinical information. However, sensitivity and specificity figures even for TPS are probably not high enough to be of definite relevance in an individual patient. In this context, so-called objective response assessments are not perfect reflectors of true patient benefit, symptom influence and survival prolongation [27, 44, 45] . Thus, there continues to be a desire to develop new methods for early measurement of anti-tumour effects of chemotherapy. Many asymptomatic patients do not have easily measurable disease, but still desire to be actively treated due to the generally poor prognosis. In these patients, changes in TPS levels, if elevated, appear to be of value to guide the length of treatment. If TPS is to be used in clinical practice, studies to confirm our results are warranted.
